Omeros Reports Strong Q1 2026 Results with $56.1M Net Income, Driven by YARTEMLEA Launch

summarizeSummary

Omeros Corporation announced robust first-quarter 2026 financial results, achieving a net income of $56.1 million and $9.9 million in net sales from its newly launched drug, YARTEMLEA.

check_boxKey Events

• Shift to Profitability

  Reported Q1 2026 net income of $56.1 million ($0.78 per share), a significant improvement from a $33.5 million net loss in Q1 2025. Non-GAAP adjusted net loss was $17.1 million.

• Successful YARTEMLEA Launch

  Generated $9.9 million in net sales for YARTEMLEA in its first quarter of commercial availability, indicating strong early adoption.

• Strengthened Balance Sheet

  Repaid $17.1 million of 2026 convertible notes, reducing total debt, and maintained $135.3 million in cash and short-term investments.

• Share Repurchase Program

  Repurchased 0.4 million shares for $4.2 million during the quarter, demonstrating commitment to shareholder value.

auto_awesomeAnalysis

Omeros Corporation reported a significant financial turnaround in Q1 2026, moving from a net loss to a net income of $56.1 million. This positive shift was largely supported by the successful commercial launch of YARTEMLEA, which generated $9.9 million in net sales in its first quarter on the market. The company also strengthened its balance sheet by repaying $17.1 million in debt and executing a $4.2 million share repurchase program, signaling confidence in its financial health and future prospects.